← All trials
NCT06785272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2025
- Primary completion
- Oct 31, 2027
- Completion date
- Oct 31, 2027
- First posted
- Jan 21, 2025
- Last posted
- Jan 21, 2025
- Enrollment
- 192
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- University of AlbertaCollaborator
- University of TorontoOfficial
- McMaster UniversityCollaborator
- University of TorontoCollaborator
- University of CalgaryCollaborator
- University of TorontoSponsor investigator
- St. Justine's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.